Live feed11:20:00·6mPRReleasevia QuantisnowBiogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus ErythematosusByQuantisnow·Wall Street's wire, on your screen.BIIB· Biogen Inc.Health Care
